- Home
- LFS vs NRXS Comparison
LFS vs NRXS Comparison
Compare LFS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LFS | NRXS |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | Japan | United States |
| Employees | 1055 | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.9M | 78.9M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | LFS | NRXS |
|---|---|---|
| Price | $2.76 | $7.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.7M | 158.4K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $1.58 | $2.20 |
| 52 Week High | $12.49 | $9.33 |
Technical Indicators
Market Signals| Indicator | LFS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 46.87 |
| Support Level | $1.79 | $6.80 |
| Resistance Level | $2.90 | $8.03 |
| Average True Range (ATR) | 0.37 | 0.56 |
| MACD | 0.12 | -0.10 |
| Stochastic Oscillator | 38.44 | 21.07 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children. The company focuses on covering 13 sports like soccer, basketball, and dance and in child athletic development, club activity management for schools, and social businesses like elderly care.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).